Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Crispr Therapeutics AG    CRSP   CH0334081137

CRISPR THERAPEUTICS AG

(CRSP)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/20/2019 05/21/2019 05/22/2019 05/23/2019 05/24/2019 Date
37.69(c) 39.43(c) 38.82(c) 36.81(c) 37(c) Last
276 882 317 994 308 517 529 449 301 266 Volume
-2.94% +4.62% -1.55% -5.18% +0.52% Change
More quotes
Financials (USD)
Sales 2019 5,91 M
EBIT 2019 -203 M
Net income 2019 -199 M
Finance 2019 198 M
Yield 2019 -
Sales 2020 17,5 M
EBIT 2020 -231 M
Net income 2020 -224 M
Finance 2020 352 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales2019 296x
EV / Sales2020 91,3x
Capitalization 1 948 M
More Financials
Company
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be... 
More about the company
Surperformance© ratings of Crispr Therapeutics AG
Trading Rating : Investor Rating :
More Ratings
Latest news on CRISPR THERAPEUTICS AG
05/01CRISPR Therapeutics to Participate in Upcoming Investor Conferences
GL
04/29CRISPR Therapeutics Provides Business Update and Reports First Quarter 2019 F..
GL
02/27CRISPR Therapeutics Announces Presentations at the American Association for C..
GL
02/25CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and F..
GL
02/25CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Prog..
GL
02/21CRISPR Therapeutics Proposes New Members to the Board of Directors
GL
01/22CRISPR Therapeutics and ProBioGen Sign Collaboration and License Agreement to..
GL
2018CRISPR Therapeutics to Participate in Upcoming Investor Conferences
GL
2018CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2018 F..
GL
2018CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold on t..
GL
More news
Analyst Recommendations on CRISPR THERAPEUTICS AG
More recommendations
Sector news : Biotechnology & Medical Research - NEC
05/21Global chemical firms urged to source responsibly after lethal China blast - ..
RE
05/15GILEAD SCIENCES : Novartis gets approval to sell Kymriah in Japan for $306,000
RE
05/13REGENERON PHARMACEUTICALS : Says FDA Approves Eylea Injection for All Diabetic R..
DJ
05/10PATRICK THOMAS : Biotech Industry Woos Talent With Top Pay -- WSJ
DJ
05/09PATRICK THOMAS : Biotech Is Place to Be for Top Salaries
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart CRISPR THERAPEUTICS AG
Duration : Period :
Crispr Therapeutics AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CRISPR THERAPEUTICS AG
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Average target price 56,8 $
Spread / Average Target 54%
EPS Revisions
Managers
NameTitle
Samarth Kulkarni Chief Executive Officer & Director
Rodger Novak Chairman & President
Kala Subramanian Senior Vice President-Operations
Michael John Tomsicek CFO & Principal Accounting Officer
Tony W. Ho Executive VP, Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
CRISPR THERAPEUTICS AG29.51%1 948
IQVIA HOLDINGS INC17.40%26 900
LONZA GROUP24.03%23 473
CELLTRION, INC.--.--%19 604
INCYTE CORPORATION28.56%17 530
EXACT SCIENCES CORPORATION48.97%12 511